Stock ALZ ALZINOVA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Alzinova AB

Equities

ALZ

SE0007413455

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:22:42 2024-04-26 am EDT 		5-day change 1st Jan Change
1.156 SEK -32.00% Intraday chart for Alzinova AB -33.33% -61.91%
Apr. 25 Sweden’s Alzinova Says CEO to Step Down by July-end MT
Apr. 25 Kristina Torfgård Leaves the CEO Position At Alzinova Ab, Effective July 31, 2024 CI

Valuation

Fiscal Period: December 2018 2020 2021 2023 2024 2025
Capitalization 1 128.2 117.6 101.6 51.48 51.48 -
Enterprise Value (EV) 1 128.2 117.6 73.56 113.1 -17.62 11.48
P/E ratio -30.8 x -18.8 x -13.4 x -7.4 x 11.6 x -0.61 x
Yield - - - - - -
Capitalization / Revenue - - - 501 x 1 x -
EV / Revenue - - - 419 x -0.34 x -
EV / EBITDA -30.6 x - -9.78 x -1.7 x -1.76 x -0.14 x
EV / FCF - - -2.71 x -3.25 x -4.41 x -0.14 x
FCF Yield - - -36.9% -30.8% -22.7% -732%
Price to Book - - - - 0.39 x 0.39 x
Nbr of stocks (in thousands) 5,478 15,267 15,776 44,531 44,531 -
Reference price 2 23.40 7.700 6.440 1.156 1.156 1.156
Announcement Date 2/26/19 2/25/21 2/24/22 2/28/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2020 2021 2022 2023 2024 2025
Net sales 1 - - - - 0.27 51.5 -
EBITDA 1 -4.19 - -7.519 - -15 10 -84
EBIT 1 - - -7.519 - -16.52 10 -84
Operating Margin - - - - -6,119.26% 19.42% -
Earnings before Tax (EBT) 1 - - -7.552 -13.09 -16.48 10 -84
Net income 1 - -6.5 -7.552 -13.09 -16.48 6.5 -84
Net margin - - - - -6,103.7% 12.62% -
EPS 2 -0.7600 -0.4100 -0.4800 - -0.4100 0.1000 -1.900
Free Cash Flow 1 - - -27.14 - -34.82 4 -84
FCF margin - - - - -12,895.19% 7.77% -
FCF Conversion (EBITDA) - - - - - 40% -
FCF Conversion (Net income) - - - - - 61.54% -
Dividend per Share - - - - - - -
Announcement Date 2/26/19 2/25/21 2/24/22 2/23/23 2/28/24 - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - -
Net Cash position 1 - - 28 - 22 69.1 40
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - - -27.1 - -34.8 4 -84
ROE (net income / shareholders' equity) - - - - -15% 39% -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - 2.930 2.960
Cash Flow per Share - - - - - - -
Capex 9.41 - - - - - -
Capex / Sales - - - - - - -
Announcement Date 2/26/19 2/25/21 2/24/22 2/23/23 2/28/24 - -
1SEK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ALZINOVA AB Stock Alzinova AB
-61.91% 4.7M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALZ Stock
  4. Financials Alzinova AB